Form 4: Mersana SVP Disposes Shares, Options Post-Merger

Mohan Bala, SVP of Mersana Therapeutics, reported the disposition of all his common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Summary

• Mohan Bala, SVP, Chief Development of Mersana Therapeutics, Inc., reported changes in his beneficial ownership on January 6, 2026.
• Mersana Therapeutics, Inc. completed its merger with Day One Biopharmaceuticals, Inc., becoming a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.
• Mersana shareholders received $25.00 per share in upfront cash and one non-tradeable contingent value right (CVR) per share, with potential additional payments of up to $30.25 per CVR.
• Options to purchase Mersana common stock with an exercise price less than $25.00 per share (Cash-Out Options) were fully vested, cancelled, and converted into the right to receive cash (Offer Price minus exercise price).
• Options with an exercise price equal to or greater than $25.00 per share (Out-of-the-Money Options) became fully vested and exercisable for a limited period, then cancelled if not exercised.
• Restricted Stock Units (RSUs) were automatically cancelled and converted into the right to receive the Offer Price.
• Mohan Bala disposed of 2,927 shares of common stock, 32,546 stock options, and 4,950 restricted stock units.
• Following these transactions, Mohan Bala beneficially owns 0 shares of common stock and 0 derivative securities of Mersana Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, which provides a clear exit for shareholders with an upfront cash payment and potential future upside via CVRs. While some options were cancelled without consideration, the overall transaction provides value for most equity holders. The company is no longer independent, which could be seen as a negative for some, but the terms appear structured to provide a reasonable outcome given the context of an acquisition.

Positives

• Mersana shareholders received an upfront cash consideration of $25.00 per share as part of the merger.
• There is a potential for additional payments of up to $30.25 per CVR upon the achievement of specified milestones, offering future upside.
• Cash-Out Options and Restricted Stock Units held by insiders were converted into cash, providing value to their holders.

Negatives

• Out-of-the-Money Options that were not exercised by the specified deadline were cancelled without any consideration.
• Mersana Therapeutics, Inc. is no longer an independent publicly traded company, having become a wholly-owned subsidiary.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of future specified milestones, which may not occur.
• CVRs are non-tradeable, limiting liquidity for holders.

Future Outlook

The future outlook for Mersana Therapeutics, Inc. as an independent entity is concluded, as it has become a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. The future value for former Mersana shareholders holding CVRs depends on the achievement of specified milestones by Day One Biopharmaceuticals.

Industry Context

This merger represents a common trend of consolidation within the biotechnology and pharmaceutical industry, where larger companies acquire smaller ones, often to gain access to their pipeline assets or specialized technologies. The inclusion of Contingent Value Rights (CVRs) is a frequently used mechanism in biotech M&A to bridge valuation gaps and share future development risks and rewards between the acquiring and target companies' shareholders.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech mergers is a standard practice, observed in numerous acquisitions such as Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia. This structure allows the acquiring company to mitigate risk associated with pipeline assets while offering target shareholders potential upside if development milestones are met.
• The combination of an upfront cash component ($25.00 per share) with a potential additional $30.25 per CVR suggests a total potential value of $55.25 per share. This hybrid payment structure is typical for biotech acquisitions where a base value is paid, and further payments are contingent on clinical, regulatory, or commercial successes.

Stakeholder Impact

• Shareholders: Received upfront cash and CVRs, ending their direct equity ownership in Mersana Therapeutics, Inc.
• Employees: Equity compensation (options, RSUs) was converted or cancelled according to merger terms. Their employment status and roles within the new subsidiary structure would be impacted.
• Company (Mersana Therapeutics, Inc.): Ceased to be an independent public entity, becoming a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.

Next Steps

• Achievement of specified milestones for CVR holders to receive additional payments.
• Integration of Mersana Therapeutics, Inc. into Day One Biopharmaceuticals, Inc.

Key Dates

Keywords

Mersana Therapeutics, MRSN, Day One Biopharmaceuticals, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Restricted Stock Units, CVR, Contingent Value Rights, Mohan Bala, Corporate Governance